ライフサイエンスコーパス: were assessed at baseline

1 study (conducted from August 21, 2008, to January 5, 2012) were assessed at baseline, 1 month, and 1 year.

2 and analysis), blood pressure, and phenolic acid absorption were assessed at baseline and at 1, 2, 3, 5, and 8 h postcons

3 Fifty-five children (2 to 7 years of age) were assessed at baseline and at 12 months and grouped as car

4 immunity (CMI), and immunoglobulin G (IgG) antibody avidity were assessed at baseline and 1 month and 1 year after MMR3 r

5 Participant demographics, drug use, and risk behaviours were assessed at baseline and every 3 months using an audio c

6 SES indicators (education and income) and CAC were assessed at baseline.

7 Children were assessed at baseline (ages 8-10 years) and 2 years later

8 20 years enrolled in the Inherited Neuropathies Consortium were assessed at baseline and 2 years.

9 ; lower scores indicate reduced functional ability) domains were assessed at baseline and every 9 months up to a maximum

10 Home dust mite allergen levels (<10 or >/=10 mug/g dust) were assessed at baseline, and (>/=1) severe asthma exacerbat

11 Retinal structure and function were assessed at baseline, 1 week, and 1 month using optical

12 Iron markers, fecal pH, and bacterial groups were assessed at baseline and 3 wk.

13 atigue and pain) and quality of life (as related to health) were assessed at baseline and at 6 and 12 weeks.

14 iphosphate (CT-ADP), a point-of-care measure of hemostasis, were assessed at baseline and 5 minutes after each step of th

15 emory, executive function, and attention and hyperactivity, were assessed at baseline and postintervention.

16 on, vitamin A, anemia, malaria, and anthropometric measures were assessed at baseline and at 12 mo of follow-up.

17 All outcome measures were assessed at baseline, postintervention, and 3-month and

18 am Study, the presence, number, and location of microbleeds were assessed at baseline on brain MRI of 4759 participants a

19 ry, executive function, attention, blood pressure, and mood were assessed at baseline and at 6 and 12 wk.

20 Frequencies of consuming midday or evening MPAH were assessed at baseline and during follow-up.

21 n A-I, cholesterol efflux capacity, and HDL particle number were assessed at baseline and 12 months in a nested case-cont

22 Outcomes were assessed at baseline and after 3, 6, and 12 months.

23 Outcomes were assessed at baseline, after treatment, and at 6-month fo

24 Clinical and echocardiographic outcomes were assessed at baseline, discharge, and 30 days.

25 Clinical and echocardiographic outcomes were assessed at baseline, post-procedure, and 30 days.

26 Clinical parameters were assessed at baseline and 3 and 6 months after therapy.

27 The following clinical parameters were assessed at baseline and 45, 90, and 180 days after non-

28 Clinical, functional, and inflammatory parameters were assessed at baseline and at yearly visits.

29 Anthropometric, metabolic, and periodontal parameters were assessed at baseline and re-evaluated at 3 and 6 months.

30 come measures as well as secondary psychological parameters were assessed at baseline and 3 months after intervention.

31 Clinical and radiographic parameters were assessed at baseline and 12 months after treatment.

32 Participants were assessed at baseline and 3- and 6-month follow-up for gl

33 Participants were assessed at baseline and were followed up at 3, 6, and 9

34 Participants were assessed at baseline, week 12, week 24 (primary outcome)

35 Thyroid nodule volume, US structure, and Doppler pattern were assessed at baseline, at 1 week, and at 1, 3, and 6 mont

36 e material (SHRM), and pigment epithelial detachment (PED), were assessed at baseline to determine whether they influence

37 Clinical scores and autobiographical memory performance were assessed at baseline and 1 week after the final rtfMRI-n

38 Cognitive function, mood, and blood pressure were assessed at baseline and follow-up by using standardized

39 Metabolic profiles were assessed at baseline and after 3 months of treatment.

40 As an exploratory endpoint, PROs were assessed at baseline, week 9, and every 6 weeks thereaft

41 ria (>1 g/d), systemic disease, and CKD stage (at referral) were assessed at baseline.

42 Asthma control per GINA and the use of healthcare resources were assessed at baseline and three-monthly visits up to 1 ye

43 Knowledge and skills in neonatal resuscitation were assessed at baseline and at 6 and 12 months after the in

44 pha (8-isoPGF2alpha), and epigenetic regulation of p66(Shc) were assessed at baseline and follow-up.

45 In 1,188 subgingival plaque samples, 11 bacterial species were assessed at baseline, including Aggregatibacter actinomy

46 astern Cooperative Oncology Group (ECOG) performance status were assessed at baseline (median = 3.8 months before death)

47 PTSD symptoms were assessed at baseline and approximately 1, 3, 6, and 12 m

48 ance imaging responses during an N-back working memory task were assessed at baseline and at the end of treatment.

49 color vision, sleep parameters, and neurocognitive testing) were assessed at baseline.

50 Youths were assessed at baseline and at four 6-month intervals with